Sarah Green
Family · Spring City, TNNPI 1053043372
Payments from drug & device makers
Across 153 payments — averaging $15.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$374
- Lilly USA, LLC$305
- Novo Nordisk$258
- GSK$169
- Bayer$162
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$140
- plus $952 from 21 others
What the payments were for
- Food & beverage$2,361100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 32 | $374 |
| Lilly USA, LLC | 24 | $305 |
| Novo Nordisk | 14 | $258 |
| GSK | 11 | $169 |
| Bayer | 9 | $162 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $140 |
| AstraZeneca | 7 | $105 |
| Xeris Pharmaceuticals, Inc. | 5 | $89 |
| Phathom Pharmaceuticals, Inc. | 5 | $83 |
| Otsuka America Pharmaceutical, Inc. | 3 | $72 |
| Verona Pharma, Inc. | 2 | $60 |
| Pfizer | 3 | $57 |
| Amgen | 3 | $49 |
| Inspire Medical Systems, Inc. | 2 | $49 |
| Boehringer Ingelheim | 3 | $48 |
| Lundbeck LLC | 2 | $44 |
| Antares Pharma, Inc. | 2 | $43 |
| Dexcom, Inc. | 2 | $40 |
| Myovant Sciences Inc. | 2 | $39 |
| Sumitomo Pharma America, Inc. | 2 | $38 |
| Tolmar, Inc. | 2 | $31 |
| Pacira Pharmaceuticals Incorporated | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Medtronic | 1 | $18 |
| Merck | 1 | $18 |
| Cipher Pharmaceuticals US LLC | 1 | $17 |
| Boston Scientific | 1 | $14 |
How this compares
$2,361 in reported general payments places this provider in the 80th percentile of 6,706 family providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 28 | $32,064 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $22,604 |
| JardianceEmpagliflozin | 15 | $22,426 |
| OzempicSemaglutide | 14 | $20,261 |
| TrulicityDulaglutide | 17 | $18,316 |
| EliquisApixaban | 12 | $9,001 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 56 | $1,666 |
| Atorvastatin Calcium | 65 | $767 |
| Metoprolol Succinate | 31 | $553 |
| Omeprazole | 45 | $496 |
| Rosuvastatin Calcium | 46 | $437 |
| Duloxetine Hcl | 21 | $402 |
| Pantoprazole Sodium | 32 | $401 |
| Ramipril | 33 | $345 |
| Potassium Chloride | 19 | $334 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $305 | $50,38045 claims |
| GSKTrelegy Ellipta | $169 | $22,60428 claims |
| Boehringer IngelheimJardiance | $48 | $22,42615 claims |
| Novo NordiskOzempic | $258 | $20,26114 claims |
| PfizerEliquis | $57 | $9,00112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,706 family providers in Tennessee.
Other family in Spring City
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.